3 terminated, 2 withdrawn. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 3, Withdrawn 2 |
Follow parsaclisib: new trials by email Literature Review of parsaclisib trials Research Report on parsaclisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) parsaclisib, rituximab, obinutuzumab - Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | Phase 3 | Withdrawn | Incyte Corporation | 2022-12-30 | 2022-07-18 | |
| Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia parsaclisinib, placebo - Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 3 | Terminated | Incyte Corporation | 13 | 2022-03-15 | 2025-11-03 |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma parsaclisib, rituximab, bendamustine - Mantle Cell Lymphoma | Phase 3 | Withdrawn | Incyte Corporation | 2022-03-11 | 2022-04-29 | |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 177 | 2021-05-26 | 2025-10-02 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 252 | 2021-05-24 | 2025-10-21 |
Myeloproliferative Disorders (2) · Primary Myelofibrosis (2) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1)
Austria (3) · Belgium (3) · France (3) · Germany (3) · Israel (3) · Italy (3) · Japan (3) · Poland (3) · Spain (3) · United Kingdom (3) · United States (3) · China (2) · Finland (2) · Norway (2) · South Korea (2)
Albert Assad, M.D (1) · Albert Assad, M.D. (1) · Kathleen Butler, MD (1)